Detalhe da pesquisa
1.
Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
Br J Dermatol
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048385
2.
The disease burden of pediatric patients with atopic dermatitis in Japan.
Pediatr Dermatol
; 40(5): 851-856, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581214
3.
The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study.
J Pediatr
; 246: 220-226.e5, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35490745
4.
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitis.
Allergy
; 77(11): 3388-3397, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35815904
5.
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis.
Acta Derm Venereol
; 102: adv00726, 2022 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393631
6.
Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study.
Ann Allergy Asthma Immunol
; 126(4): 417-428.e2, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33421555
7.
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Acta Derm Venereol
; 101(11): adv00585, 2021 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618162
8.
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
J Am Acad Dermatol
; 82(6): 1328-1336, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135208
9.
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
J Drugs Dermatol
; 18(8): 804-813, 2019 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31424712
10.
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11â years with severe atopic dermatitis.
Br J Dermatol
; 189(2): 238-240, 2023 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120724
11.
Sub-optimal Application of a High SPF Sunscreen Prevents Epidermal DNA Damage in Vivo.
Acta Derm Venereol
; 98(9): 880-887, 2018 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29944164
12.
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial.
J Am Acad Dermatol
; 84(2): 495-497, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387659
13.
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.
Acta Derm Venereol
; 101(7): adv00504, 2021 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34043020
14.
Dupilumab Treatment in Pediatric Patients Aged 6-11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review.
Drug Des Devel Ther
; 18: 277-289, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38333897
15.
Implications of Atopic Dermatitis on the Quality of Life of 6-11 Years Old Children and Caregivers (PEDI-BURDEN).
J Asthma Allergy
; 16: 383-396, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37077900
16.
Impact of the Family and Household Environment on Pediatric Atopic Dermatitis in Japan.
J Clin Med
; 12(8)2023 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37109324
17.
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
Am J Clin Dermatol
; 24(5): 787-798, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37300760
18.
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
JAMA Dermatol
; 159(3): 255-266, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36723913
19.
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year.
Dermatol Ther (Heidelb)
; 12(1): 9-13, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994968
20.
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.
JID Innov
; 2(5): 100131, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36059592